<DOC>
	<DOCNO>NCT00023153</DOCNO>
	<brief_summary>This study evaluate safety effectiveness adefovir plus lamivudine chronic hepatitis B infection people without HIV infection . Lamuvidine , FDA-approved treatment hepatitis B infection , also work HIV . In patient , hepatitis B virus ( HBV ) continue reproduce despite lamivudine treatment . Adefovir experimental drug inhibits HBV replication may work strain virus become resistant lamivudine . Patients 21 year age older active hepatitis B infection despite treatment lamivudine least 1 year may eligible 48-week study . Patients without HIV infection may participate . Candidates screen medical history , blood urine test , liver ultrasound exam , electrocardiogram ( EKG ) chest X-ray . Participants physical examination , review medical history , blood test , 24-hour urine collection . They admit hospital liver biopsy determine receive study drug . For procedure , patient give sedative relaxation . The skin biopsy numb anesthetic biopsy needle pass rapidly liver collect tissue specimen . Patients monitor hospital overnight possible complication . After discharge , return home begin take study medication . Patients randomize two treatment group . One group take 10 milligrams/day adefovir mouth , take placebo-a lookalike pill active ingredient . Both group also take 150 mg lamivudine mouth L-carnitine pill liquid . Patients HIV infection continue take antiretroviral therapy well . Patients follow clinic study week 2 , 4 , 8 , 12 , 16 , 20 , 24 , 28 , 32 , 36 , 40 44 blood urine test determine safety drug evaluate response treatment . On week 48 , repeat 24-hour urine test repeat liver biopsy do . At end 48 week , patient may continue receive adefovir another 48 week possibly longer . All participate extension phase receive active adefovir , regardless whether previously take adefovir placebo . All patient option enroll separate study examine level HBV ( level HIV HIV-infected patient ) blood immediately start treatment determine initial level predict later outcome . This involve seven additional visit , participant compensate . At visit , blood drawn study day 0 ( start drug treatment ) , 1 , 3 , 5 , 7 , 10 21 HIV HBV viral load specialize immunology test .</brief_summary>
	<brief_title>Lamivudine Adefovir Treat Chronic Hepatitis B Infection People With Without HIV Infection</brief_title>
	<detailed_description>This clinical trial examines addition adefovir dipivoxil lamivudine regimen treat chronic hepatitis B infection . Two patient population separately recruit : HIV-infected ( 40 subject ) HIV-uninfected ( 20 subject ) . HIV-infected patient enrol randomize , placebo control study safety efficacy addition adefovir lamivudine treatment chronic hepatitis B subject hepatitis B virus ( HBV ) viral load least one million copies/mL despite least one year lamivudine therapy . A similar population HIV-uninfected subject treat open-label adefovir 10 mg daily one year . These HIV-negative subject serve control group immunological comparison HIV-positive group treat adefovir . HIV-infected subject randomly allocate receive adefovir 10 mg daily one year match placebo . At end one year , HIV-infected patient may choose receive open-label adefovir , HIV-uninfected patient option continue open-label drug respond treatment . Patients may decompensated cirrhosis cause liver disease hepatitis C. Liver biopsy perform prior study end one year . HIV-positive subject whose liver biopsy demonstrate cirrhosis randomize treat open-label adefovir 10 mg daily . The purpose study evaluate safety efficacy lamivudine plus adefovir compare continued lamivudine HIV-infected patient , compare response HIV-uninfected HIV-infected subject , obtain specimens study immune response HBV . HIV-infected patient receive lamivudine 150 mg bid plus adefovir 10 mg qd ( placebo ) HIV-uninfected subject receive lamivudine 100 mg qd plus adefovir 10 mg qd . L-carnitine supplementation use low serum carnitine level document . Additionally , patient option enrol sub-study assess kinetics viral load response study drug . Specimens store possible future determination adefovir level use evaluate HBV HIV resistance adefovir . Patients discontinue study drug initiate commerically available anti-HBV medication ( include adefovir ) monitor safety least additional 24 week . The primary study endpoint comparison absolute HBV viral load Week 48 placebo adefovir HIV-positive patient group , HIV-negative population , comparison absolute HBV viral Week 48 versus baseline . Secondary endpoint include safety , liver pathology , transaminase level . Adefovir discontinue toxicity ; dose reduction . A DSMB oversee trial toxicity .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>INCLUSION CRITERIA : Age great equal 18 year Infection HBV HBV viral load great 1.0 x 10 ( 6 ) copies/mL Roche assay screen HIV infect uninfected If HIV infect : CD4 great equal 100 VL less equal 10,000 screen ; No antiretroviral change 12 week prior entry anticipate change 12 week study . Have physician ( ) outside NIH provide routine , well HIV ( applicable ) liver specific , care . Able return NIH study visit Receiving lamivudine dose least 100 mg qd great equal one year prior enrollment ( dose interruption great 1 month total previous year interruption 3 month prior study entry ) Serum creatinine le 1.5 mg/dL 1.2 less equal ALT ( SGPT ) less equal 7 X ULN ( current NIH lab value 49287 U/L inclusive ) screen Direct bilirubin less equal 1.0 mg/dL Serum phosphorus great equal 2.2 mg/dL ( normal range NIH 2.34.3 mg/dL ) Neutrophil count great equal 750 cells/mm ( 3 ) Platelets great equal 70,000/mm ( 3 ) INR le equal 1.5 Hemoglobin great equal 10 mg/dL If capable pregnancy : use effective contraception study : effective contraception method include abstinence , surgical sterilization either partner , barrier method diaphragm , condom , cap sponge , use hormonal contraception . If HIV infect use hormonal contraception , must receive antiHIV regimen alter metabolism hormonal contraception . Willing able provide write informed consent Willing undergo hepatic biopsy start end study . The initial protocol biopsy require subject provide pathologic slide biopsy perform within six month History Physical visit find Liver Disease Section NIH 's pathologist adequate study . EXCLUSION CRITERIA : Prior use ADV , tenofovir , cidofovir Decompensated cirrhosis : ChildPugh Class B C cirrhosis ; Class A Score = 5 acceptable ; Class A Score = 6 acceptable long secondary encephalopathy ascites Active serious systemic infection HIV HBV Liver disease cause reason hepatitis B e.g. , HCV , HDV , Wilson 's , hemochromatosis , autoimmune hepatitis ( ANA great equal 3 EU ) except history drugassociated hepatitis discontinuation causative agent History encephalopathy , varix , heart failure , ascites Current history clinical pancreatitis New AIDSdefining event esophageal candidiasis diagnose within 1 month prior baseline Treatment immunomodulator drug ( interleukin , corticosteriods indication treatment adrenal insufficiency ) 4 week prior baseline . GCSF epoetin use permit . AntiHBV therapy lamivudine ( emtricitabine , lobucavir , entecavir , HBIG , clevudine , MCC478 ) exception interferon alpha , famciclovir foscarnet end 12 week prior screen . Hepatic mass suggestive hepatocellular carcinoma Alpha fetoprotein great 200 ng/ml Evidence gastrointestinal malabsorption chronic nausea vomit Current alcohol substance abuse potentially could interfere patient compliance Malignancy cutaneous Kaposi 's sarcoma , skin cancer treat resection HPVassociated carcinoma situ Bowen 's disease 5 year prior enrollment History clinically significant renal dysfunction within previous 12 month prior baseline Concomitant therapy aminoglycosides , amphotericin B , cisplatinum , IV pentamidine , vancomycin , systemic chemotherapeutic agent , probenecid nephrotoxic agent Proteinuria ( great equal 3+ ) Positive PCR test hepatitis C Antibodies hepatitis D ( delta hepatitis ) Pregnancy breastfeed . Pregnancy test must negative within two week prior dose adefovir placebo . History organ bone marrow transplantation Any systemic illness make unlikely subject able return NIH require study visit</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2004</verification_date>
	<keyword>Drug Resistance</keyword>
	<keyword>Viral Load</keyword>
	<keyword>Liver</keyword>
	<keyword>Immunology</keyword>
	<keyword>Liver Histology</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>HBV</keyword>
	<keyword>HIV</keyword>
</DOC>